In ovarian cancer patients, the mutations in BRCA1/2 and mismatch repair (MMR) genes, as well as homologous recombination deficiency (HRD) status and platinum resistance of the tumor, should be evaluated to predict the treatment response. The gene discussed is BRCA1; the disease is ovarian carcinoma.